Trial NCT02616185

View at ClinicalTrials.gov 
Org. Study IDs: B7791001
Secondary IDs: PRCA VBIR FIP STUDY

Last trial update was posted on 2023-11-02

MeSH Interventions

Tremelimumab

MeSH Conditions

Prostatic Neoplasms

Other Conditions


Stopping Reasons

Due to strategic evaluation of PF-06753512 (VBIR-1) within context of Pfizer's oncology portfolio, decision not based on any safety or regulatory concerns.

Limitations And Caveats

The study was terminated on 20 August 2020 by the sponsor. The decision to terminate this study was based on the results of a strategic evaluation of VBIR-1 within the current Pfizer oncology portfolio. This decision was not based on any safety or regulatory concerns with the treatment of participants with VBIR-1.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID